Comparing cellular bone matrices for posterolateral spinal fusion in a rat model.

Area of Science:

• Biomaterials Science
• Orthopedic Surgery
• Regenerative Medicine

Background:

• Cellular bone matrices (CBMs) are emerging allografts for bone regeneration.
• CBMs offer an osteoconductive scaffold, growth factors, and viable cells.
• They are explored as alternatives to autografts in spinal fusion.

Purpose of the Study:

• To compare the efficacy of six commercial human CBMs in promoting spinal fusion.
• To evaluate CBM performance against a syngeneic rat bone control.
• To assess new bone formation and fusion stability.

Main Methods:

• A posterolateral spinal fusion model in athymic rats was used.
• Six CBMs (Trinity ELITE, ViviGen, Cellentra, Osteocel Pro, Bio4, Map3) were implanted.
• Radiographic, microCT, and histological analyses were performed at 6 weeks.

Main Results:

• Trinity ELITE and Cellentra demonstrated higher fusion rates (8/15 and 11/15, respectively) than other CBMs.
• Significant increases in bone volume were observed with Trinity ELITE (65%) and Cellentra (73%).
• Other CBMs showed limited or no fusion and bone regeneration.

Conclusions:

• Trinity ELITE and Cellentra were significantly more effective in promoting spinal fusion.
• Substantial variability exists in the fusion potential of different CBM products.
• These findings highlight the importance of CBM selection for spinal fusion procedures.